Delving into the Latest Updates on C-9054 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Antipsychotic therapeutic

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Behavioural disordersPsychotic Disorders

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization-

Inactive Organization

Merck Sharp & Dohme Corp.

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

This randomized, double-blind, placebo-controlled parallel group study will assess the effect on biomarkers measures of cognitive dysfunction, the clinical efficacy and safety of RO4917838 in participants with schizophrenia and schizoaffective disorder. Participants will be randomized to receive either RO4917838 (10 milligrams [mg] daily orally) or placebo for 6 weeks, in addition to their stable antipsychotic medication. Anticipated time on study treatment is 6 weeks.

Start Date01 Nov 2010

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

NCT01556763

/ CompletedPhase 1

A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics

This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo when given with the patient's usual antipsychotic medication.

Start Date01 Apr 2008

Sponsor / Collaborator

FORUM Pharmaceuticals, Inc.

100 Clinical Results associated with C-9054

Login to view more data

100 Translational Medicine associated with C-9054

Login to view more data

100 Patents (Medical) associated with C-9054

Login to view more data

100 Deals associated with C-9054

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Behavioural disorders	Phase 2	-	Merck Sharp & Dohme Corp.	-
Psychotic Disorders	Phase 2	United States	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01556763 (CTgov)	Phase 1	Central Nervous System Diseases \| Schizoaffective disorder \| Schizophrenia	21	Placebo+Antipsychotic therapy (Placebo)	(sswpwbeurt) = svbfmuridw bryvkhaxkm (jgfwtjownj, tyaprbehdn - unyntpthrr) View more	-	21 Jun 2012
				EVP-6124 (1.0 mg/day)+Antipsychotic therapy (EVP-6124 (1.0 mg/Day))	(sswpwbeurt) = ysiittikex bryvkhaxkm (jgfwtjownj, yfhfvcoxnp - vpsjoefrty) View more